Bethesda North Marriott Hotel and Conference Center
5701 Marinelli Road,
North Bethesda, MD 20852
USA
DIA/FDA Oligonucleotide-Based Therapeutics Conference
Call for Poster Abstracts
Read Abstract Details | Submit
Abstract Submission Deadline: The week of February 9, 2022
Notification: Week of February 28, 2022
Forum Dates: April 25-27
Location: North Bethesda, MD
Questions: Contact Jessica.Roman@DIAglobal.org
Poster Submission Overview and Topics
The DIA/FDA Oligonucleotide-Based Therapeutics Conference Program Committee welcomes abstracts based on the primary interest area topics in support of the following core interest areas: Nonclinical, clinical, and CMC.
Nonclinical Track
The nonclinical sessions are designed to provide updates and discussion on recent advancements in nonclinical development of oligonucleotide therapeutics. All mechanisms of RNA targeting therapeutics will be represented with a particular interest in delivery to nonhepatic tissues.
Clinical Development Track
These sessions will provide updates on the recent progress made with oligonucleotides in the clinic. Programs in various stages of development will highlight the challenges faced, lessons learned, and offer potential solutions and innovative ideas for clinical development of oligonucleotide therapeutics.
Chemistry, Manufacturing, and Controls (CMC) Track
The CMC track will cover a wide range of current oligonucleotide science and feature expert speakers from industry and regulatory agencies.
Poster submissions may include the following oligonucleotide-related topics:
- Assay Development and Optimization
- Clinical Pharmacology, including Oligonucleotide ADME
- Clinical Safety
- Formulations
- Hot Topics in Oligonucleotide Research
- Impurities
- Manufacturing
- Nonclinical Efficacy Models
- Toxicology, Including Updates in Oligo Toxicology (Clinical and Nonclinical)
- Novel Mechanisms for Intervention
- Novel Oligonucleotide Therapeutics
- Oligonucleotide Conjugation and Tissue Targeting
- Regulatory Affairs, Including Oligonucleotide Regulatory Guidance
- Oligonucleotide Therapeutics for:
- Rare Diseases
- Immuno-oncology
- Metabolic and Cardiovascular Diseases
- Neuromuscular Conditions
- Targeting and Delivery, Including Target Identification Screening Methods (Discovery)
- Translational Experience
